Veradermics Inc.
PublicVeradermics Inc. is now publicly traded
The data on this page reflects Veradermics Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 3, 2026
Last Round
Follow-on Offering
May 1, 2026
Total Funding Raised
$585.5M
Company Overview
Veradermics Inc. is a biopharmaceutical company that develops first-in-class therapeutics for dermatologic and aesthetic conditions, including pattern hair loss, common warts, and molluscum contagiosum.
AI Layer
Non-AI
Keywords
Veradermics Inc. Comparables
Compare Veradermics Inc. with similar companies based on industry and business-model similarity.
No public comparables are available for Veradermics Inc.. Request access to learn about comparables coverage.
Book a demoFor institutional investors. Book with your work email.
Veradermics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | May 1, 2026 | ||||
| IPO | Feb 3, 2026 | ||||
| Series C | Oct 16, 2025 | ||||
| Series B | Dec 11, 2024 | ||||
| Private Placement | Apr 25, 2023 | ||||
Series A | Sep 22, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Veradermics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Longitude Capital | Series B, Series C |
| Surveyor Capital | Series C |
| Connecticut Innovations | Series B, Series A |
| LifeSci Venture Partners | Series C |
| abrdn Inc. | Series C |
| Columbia Threadneedle Investments | Series C |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 12, 2026
Veradermics raises approximately $472M after its IPO to continue progressing VDPHL01 in Connecticut on Jul 6th '26.
- is_developingAug 12, 2026
As of Aug '26, the New Haven, Connecticut-based Veradermics is developing VDPHL01, an extended-release oral version of minoxidil, for men and women with pattern hair loss; late-stage studies are underway, with results expected in H2 '26 for men and H1 '27 for women.
For institutional investors. Book with your work email.
Veradermics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.